Bladder cancer today: progress—but a persistent gap

Bladder cancer is common and stubborn. In the U.S., the age-adjusted incidence is ~18 per 100,000 per year and mortality ~4 per 100,000—figures that have not fallen meaningfully in recent years. (SEER)

Care has improved across stages, yet many patients still face limited options, high recurrence, and difficult trade-offs between efficacy and quality of life.

---

How bladder cancer is treated (and where it falls short)

Non–muscle-invasive bladder cancer (NMIBC)

• • Standard approach: Tumor removal via TURBT followed by intravesical therapy. Bacillus Calmette-Guérin (BCG) remains the backbone, but recurrence is common and true “BCG-unresponsive” disease often leads to radical cystectomy. (AUAA Journals)

• • Recent approvals:
    
    • • Adstiladrin® (nadofaragene firadenovec-vncg), an intravesical gene therapy delivering IFN-α2b, FDA-approved for BCG-unresponsive CIS (Dec 16, 2022). (U.S. Food and Drug Administration, AACR Journals)
    • • N-803 (nogapendekin alfa inbakicept, ANKTIVA®) with BCG, FDA-approved for BCG-unresponsive CIS (Apr 22, 2024). (U.S. Food and Drug Administration)

• • System challenge: Ongoing BCG shortages force dose reductions, substitutions, or delays. (Bladder Cancer Advocacy Network)

• • On the horizon: Johnson & Johnson’s TAR-200 (a pretzel-shaped intravesical gemcitabine-releasing system) received FDA Priority Review in July 2025 for BCG-unresponsive HR-NMIBC with CIS; it is not yet approved. (JNJ.com)

Muscle-invasive disease (MIBC)

Curative therapy often requires radical cystectomy with or without cisplatin-based chemo, or bladder-sparing chemoradiation. A substantial fraction of patients are cisplatin-ineligible due to renal impairment, neuropathy, hearing loss, or poor performance status—estimates range from ~30% to ~50%, depending on setting and criteria. (Oxford Academic, PMC)

Advanced/metastatic urothelial carcinoma

• • New first-line standard: Enfortumab vedotin + pembrolizumab showed superior survival vs platinum-gemcitabine and received FDA approval on Dec 15, 2023. Resistance, relapse, and cumulative toxicity remain concerns. (U.S. Food and Drug Administration, AACR Journals)

• • Biomarker-guided option: Erdafitinib’s label was updated in Jan 2024 for susceptible FGFR3-altered mUC after prior systemic therapy—helpful for a subset only. (U.S. Food and Drug Administration, FDA Access Data)

• • Maintenance immunotherapy: Avelumab after platinum chemo improves overall survival, but many patients still progress. (New England Journal of Medicine)

Bottom line: Despite meaningful wins, patients still face high recurrence in NMIBC, morbid surgery in MIBC, and limited durability in metastatic disease—compounded by supply constraints (BCG) and biomarker-restricted options (FGFR3).

---

Why unmet need remains high

• • Recurrence & progression: NMIBC recurrence remains common even with optimal care; progression to muscle-invasive disease can be life-changing. (AUAA Journals)

• • Access & tolerability: BCG shortages and cisplatin ineligibility exclude many from “best available” care. (Bladder Cancer Advocacy Network, PMC)

• • Limited targets: Precision therapies (e.g., FGFR3) help a fraction of patients; most lack an actionable biomarker. (FDA Access Data)

• • Durability: Even with powerful regimens like EV + PD-1, resistance and relapse are frequent, underscoring the need for orthogonal mechanisms. (AACR Journals)

---

Where Ymmunobio’s platform could change the game

Ymmunobio is building a tumor-targeted platform centered on NPTXR, a surface protein reported across multiple solid tumors—including bladder urothelial carcinoma—with limited expression in non-tumor peripheral tissues. Public datasets (e.g., Human Protein Atlas) list NPTXR as a prognostic marker in bladder cancer; recent ASCO work also reports expression across GI and bladder cancers. (Human Protein Atlas, ASC Publications)

We’re advancing four complementary modalities—each mapped to real patient problems in bladder cancer:

1) Antibody–drug conjugates (ADCs) to debulk disease with precision

• • Why: Deliver potent payloads directly to NPTXR-positive tumor cells, aiming for deep responses while sparing healthy tissue.

• • Where it helps: MIBC and metastatic disease, including cisplatin-ineligible patients who need non-platinum options; intravesical ADC concepts could also be explored for NMIBC to maximize local exposure. (PMC)

2) Radiopharmaceuticals to reach micrometastases and resistant niches

• • Why: NPTXR-targeted α/β emitters can penetrate tumor architectures and eradicate dispersed disease with a mechanism distinct from EV + PD-1 or chemo.

• • Where it helps: Post-immunotherapy or post-EV relapse, when new mechanisms are needed. (Investigational; development underway.)

3) T-cell–engaging biologics (e.g., BiTE-like formats) for high local immune pressure

• • Why: Redirect endogenous T cells to NPTXR-positive tumor cells—without cell harvesting.

• • Bladder-specific angle: The bladder is uniquely accessible; intravesical delivery can concentrate exposure inside the organ and align with the T-cell biology already leveraged by BCG. (AACR Journals)

4) CAR-T cell therapy engineered for solid tumors

Why now: CAR-T has transformed hematologic cancers; in solid tumors, advances are addressing historic hurdles—trafficking, immunosuppression, and antigen heterogeneity. (PMC)

How our NPTXR CAR-T program is built for these hurdles:

• • Trafficking to tumors: Armoring with CXCR1/2 leverages IL-8 gradients common in urothelial and other inflamed TMEs to enhance homing and accumulation. (PMC)

• • Resisting suppression: Incorporating PD-1→CD28 switch receptors and dominant-negative TGF-βRII designs can sustain effector function in hostile microenvironments. (PMC, PubMed)

• • Sharper specificity: Logic-gated (e.g., synNotch/AND-gate) circuits can require multiple cues before full activation—addressing heterogeneity and off-tumor risks. (PMC, Frontiers)

• • Use the bladder’s accessibility: Beyond IV dosing for MIBC/metastatic disease, locoregional delivery is feasible; emerging preclinical/early-stage data show regional CAR-T (e.g., intrapleural) can be safe and active, and intravesical CAR-T is now being explored in bladder cancer models/abstracts. (PMC, AACR Journals)

Where CAR-T could slot in clinically

• • NMIBC (BCG-unresponsive): Intravesical NPTXR CAR-T to achieve bladder-sparing control when BCG, gene therapy, or emerging devices (e.g., TAR-200) are insufficient or unavailable. (JNJ.com)

• • MIBC / metastatic: IV NPTXR CAR-T—potentially after EV + PD-1—supported by trafficking/TME armor; platform synergy with our ADCs and radiopharmaceuticals enables rational sequencing and combinations. (U.S. Food and Drug Administration)

---

What success could look like

• • For NMIBC: Bladder-sparing, intravesical precision therapies that work when BCG does not—reducing progression and cystectomy rates, independent of BCG supply. The TAR-200 path highlights the value of sustained local delivery; our platform pursues distinct mechanisms (targeted biologics and cell therapy) on the same principle: high local concentration, durable control. (JNJ.com)

• • For MIBC & metastatic disease: Systemic NPTXR-targeted ADCs, radiopharmaceuticals, and CAR-T that extend survival and maintain quality of life, including for patients who cannot receive cisplatin or who relapse after EV + PD-1. (PMC, AACR Journals)

• • For the field: A modality-agnostic platform around a single, clinically relevant target—able to combine or sequence across ADC, radio-conjugates, T-cell engagers, and CAR-T as evidence accumulates.

---

Our next steps

Ymmunobio is moving rapidly to:

1. 1. finalize clinical-grade assets against NPTXR across ADC, radiopharmaceutical, T-cell engager, and CAR-T modalities;

1. 1. complete companion diagnostic development to select the right patients;

1. 1. initiate bladder-focused trials, prioritizing the greatest unmet needs (e.g., BCG-unresponsive NMIBC and cisplatin-ineligible advanced disease).

If you’re a clinician, researcher, or potential partner interested in collaborating on NPTXR-targeted approaches in bladder cancer, we’d love to connect.

---

References (selected)

• • SEER Cancer Stat Facts—Bladder (incidence/mortality). (SEER)

• • AUA/SUO NMIBC guidance (recurrence context). (AUAA Journals)

• • FDA approvals in NMIBC: Adstiladrin (Dec 16, 2022); N-803 + BCG (Apr 22, 2024). (U.S. Food and Drug Administration, AACR Journals)

• • BCG shortage overview. (Bladder Cancer Advocacy Network)

• • EV + pembrolizumab first-line approval; survival benefit (EV-302/KEYNOTE-A39). (U.S. Food and Drug Administration, AACR Journals)

• • Erdafitinib 2024 label update; FGFR3-altered mUC. (U.S. Food and Drug Administration, FDA Access Data)

• • Avelumab maintenance (JAVELIN Bladder 100). (New England Journal of Medicine)

• • Cisplatin ineligibility (30–50% depending on criteria/setting). (Oxford Academic, PMC)

• • TAR-200 FDA Priority Review (July 17, 2025). (JNJ.com)

• • NPTXR in bladder cancer (Human Protein Atlas); ASCO abstract on multi-tumor expression. (Human Protein Atlas, ASC Publications)

• • CAR-T engineering: CXCR1/2 for trafficking; PD-1→CD28 switch; dnTGF-βRII armoring; synNotch/logic-gating; locoregional delivery and intravesical CAR-T abstracts. (PMC, PubMed, AACR Journals)

---

Disclaimer: Ymmunobio programs described here include investigational candidates that have not been approved by any regulatory authority. Efficacy and safety have not been established. This blog is intended for informational purposes only and not as medical advice.